| Identification | Back Directory | [Name]
5H-Indeno[5,6-b]furan-3-acetamide, 6,7-dihydro-N-(5-methyl-2-thiazolyl)- | [CAS]
790245-61-3 | [Synonyms]
NCT02
5H-Indeno[5,6-b]furan-3-acetamide, 6,7-dihydro-N-(5-methyl-2-thiazolyl)-
2-{5h,6h,7h-indeno[5,6-b]furan-3-yl}-n-(5-methyl-1,3-thiazol-2-yl)acetamide | [Molecular Formula]
C17H16N2O2S | [MOL File]
790245-61-3.mol | [Molecular Weight]
312.39 |
| Chemical Properties | Back Directory | [density ]
1.368±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO | [form ]
Solid | [pka]
8.95±0.50(Predicted) | [color ]
Light yellow to light brown |
| Hazard Information | Back Directory | [Biological Activity]
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC)[1]. | [storage]
Store at -20°C | [References]
[1]. Dieter SM, et al. Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 2021;36(3):109394. |
|
|